Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy
Marie-Sarah
MS
Service des Maladies du Sang, Hopital Haut Leveque, CHU de Bordeaux, Pessac, France. marie-sarah.dilhuydy@chu-bordeaux.fr
Jouary
Thomas
T
Demeaux
Hélène
H
Ravaud
Alain
A
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000150:complications* / Q000276:immunology; D003881:Dermatomycoses / Q000150:complications* / Q000276:immunology; D005148:Facial Dermatoses / Q000150:complications* / Q000276:immunology; D017809:Fatal Outcome; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab